Treatment of Patients With Anxiety Disorder (0777-022)
Phase 2
Completed
- Conditions
- Generalized Anxiety Disorder
- Registration Number
- NCT00539578
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
The purpose of the study is to examine the safety and efficacy of MK0777 during treatment for Generalized Anxiety Disorder.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 270
Inclusion Criteria
- Male and Female patients ages 18 to 70
Exclusion Criteria
- Women who are breastfeeding or pregnant
- Positive result at prestudy on urine drug screen for illicit drugs
- History of alcohol or drug abuse
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of MK0777 in treating Generalized Anxiety Disorder (GAD)?
How does MK0777 GEM compare to SSRIs in efficacy and safety for GAD patients?
Are there specific biomarkers that predict response to MK0777 in phase 2 anxiety trials?
What adverse events were observed in MK0777 phase 2 trials and how were they managed?
What are related compounds or combination therapies to MK0777 for anxiety disorders?